L-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1) cas no:55-03-8
Synonyms: L-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt (9CI);Thyroxine,monosodium salt, L- (8CI);Berlthyrox;Dathroid;Droxine;Eferox;Elthyrone;Elthyroxine;Eltroxin;Euthyrox;Eutirox;L-Thyroxin Henning;L-Thyroxinemonosodium salt;L-Thyroxine sodium;L-Thyroxine sodium salt;Laevoxin;Letrox;Letter;Levaxin;Leventa;Levo-T;Levoroxine;Levothroid;Levothyrox;Levothyroxine sodium;Levotirox;Levotiroxina;Levoxyl;Monosodium thyroxine;NSC 259940;Oroxine;Puran T 4;Sodium L-thyroxine;Sodium levothyroxine;Sodium thyroxin;Sodium thyroxinate;Sodium thyroxine;Synthroid;Synthroidsodium;Synthrox;T 4KP;T4 Montpellier 100;Thevier;Throxinique;Thyradin;Thyradin S;Thyrax Duotab;Thyrex;Thyro 4;Thyrosit;Thyroxevan;Thyroxinesodium;Thyroxine sodium salt;Tiroidine;
NameL-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, sodium salt (1:1)
CAS55-03-8
SynonymsL-Tyrosine,O-(4-hydroxy-3,5-diiodophenyl)-3,5-diiodo-, monosodium salt (9CI);Thyroxine,monosodium salt, L- (8CI);Berlthyrox;Dathroid;Droxine;Eferox;Elthyrone;Elthyroxine;Eltroxin;Euthyrox;Eutirox;L-Thyroxin Henning;L-Thyroxinemonosodium salt;L-Thyroxine sodium;L-Thyroxine sodium salt;Laevoxin;Letrox;Letter;Levaxin;Leventa;Levo-T;Levoroxine;Levothroid;Levothyrox;Levothyroxine sodium;Levotirox;Levotiroxina;Levoxyl;Monosodium thyroxine;NSC 259940;Oroxine;Puran T 4;Sodium L-thyroxine;Sodium levothyroxine;Sodium thyroxin;Sodium thyroxinate;Sodium thyroxine;Synthroid;Synthroidsodium;Synthrox;T 4KP;T4 Montpellier 100;Thevier;Throxinique;Thyradin;Thyradin S;Thyrax Duotab;Thyrex;Thyro 4;Thyrosit;Thyroxevan;Thyroxinesodium;Thyroxine sodium salt;Tiroidine;
EINECS(EC#)200-221-4
Molecular FormulaC15H10I4NNaO4
Molecular Weight776.87002
storage temp2-8°C
Globally Harmonized System of Classification adn Labelling of Chemicals(GHS)
Hazardclass6.1(a)
Safety
Poison by ingestion, subcutaneous, and intraperitoneal routes. An experimental teratogen. Experimental reproductive effects. Human systemic effects: blood pressure elevation, change in heart rate, coma, convulsions, diarrhea, hypermotility, pulse rate increase, thyroid hypofunction. When heated to decomposition it emits toxic fumes of I−, NOx, and Na2O.
Safety Statements about Levothyroxine sodium (55-03-8):
S22 Do not breathe dust.
S24/25: Avoid contact with skin and eyes.
Attention:
1. Storage: Store in a cool, dry place. Store in a tightly closed container
2. Handling: Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
| 1. |
|
orl-wmn TDLo:14 mg/kg/14D-I:BAH,CVS,GIT
|
|
AJEMEN American Journal of Emergency Medicine. 3 (1985),297. |
| 2. |
|
orl-cld TDLo:900 µg/kg:BAH,SYS
|
|
AJEMEN American Journal of Emergency Medicine. 3 (1985),297. |
| 3. |
|
orl-cld TDLo:449 µg/kg:CVS,BPR
|
|
AEMED3 Annals of Emergency Medicine. 14 (1985),1114. |
| 4. |
|
orl-wmn TDLo:117 µg/kg/60D-I
|
|
AJDCAI American Journal of Diseases of Children. 138 (1984),927. |
| 5. |
|
orl-cld TDLo:20 µg/kg
|
|
AJDCAI American Journal of Diseases of Children. 141 (1987),1025. |
| 6. |
|
ipr-rat LD50:20 mg/kg
|
|
NIIRDN “Drugs in Japan. Ethical Drugs, 6th Edition 1982“ Edited by Japan Pharmaceutical Information Center. 6 (1982),905. |
| 7. |
|
scu-rat LD50:50 mg/kg
|
|
NIIRDN “Drugs in Japan. Ethical Drugs, 6th Edition 1982“ Edited by Japan Pharmaceutical Information Center. 6 (1982),905. |
